After a year of holding the option to acquire Millipede, Boston Scientific decided to do it a year before the option ran out. When the pair signed the agreement last January, Boston Scientific paid $90 million for a portion of the mitral regurgitation startup’s shares. Now, Boston Scientific is spending $325 million